Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

06 Jul 2022

Robert J Motzer, Thomas Powles, Mauricio Burotto, Bernard Escudier, Maria T Bourlon, Amishi Y Shah, Cristina Suárez, Alketa Hamzaj, Camillo Porta, Christopher M Hocking, Elizabeth R Kessler, Howard Gurney, Yoshihiko Tomita, Jens Bedke, Joshua Zhang, Burcin Simsek, Christian Scheffold, Andrea B Apolo, Toni K Choueiri

The Lancet Oncology, 2022 Jul.

Abstract link

Forse può anche interessarti